• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

    3/11/25 8:03:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email

    Latest technology offers more applications and innovation across more specialties

    MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics.

    With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics.

    With the introduction of Mako Total Hip with Advanced Primary and Revision, Stryker expands on its established Mako Total Hip offering to include a first-to-market robotic hip revision capability. In revision total hip arthroplasty (THA), the expanded Mako Total Hip application is engineered to streamline workflow and enable confidence in challenging procedures with new features such as augment and screw planning, intraoperative screw trajectory guidance and compatibility with Stryker's revision hip implant portfolio. These new capabilities are designed to help surgeons simplify hip procedures by knowing more with Mako's 3D CT-based planning, now across both primary and revision THA procedures.

    Additionally, now commercially available is Stryker's fourth generation Mako System, Mako 4, a single robotics system that delivers additional applications and innovation, designed to offer a premium clinical and operational experience compared to manual across Mako Total Hip, Total Knee, Partial Knee and Spine. Mako 4 also integrates Stryker's fourth-generation Q Guidance System, which is built on over 20 years of experience developing guidance technologies.

    "Today's advancements in Mako SmartRobotics™ build on a foundation of clinical impact, innovation and market leadership," said Keith Evans, vice president and general manager of Stryker's Mako and Enabling Technologies business. "We are thrilled to showcase and demonstrate the future of Mako, not only what it can do but who it serves – more surgeons, more patients, across more specialties and more procedures."

    Mako Spine and Mako Shoulder are the latest to join the SmartRobotics™ suite of applications. Stryker completed its first Mako Spine cases in October and continues its limited market release with full U.S. commercial launch expected in the second half of 2025. Stryker also completed Mako Shoulder's first cases at the end of last year, and the application remains in limited market release through 2025.

    AAOS 2025 Annual Meeting attendees can visit Stryker's booth (#2529) to learn more about Mako 4 and our new applications. Stryker will hold demonstrations, exhibitions and a symposium throughout the week. For more information, please visit – MakoMeansMore.com.

    About Stryker

    Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

    Media contact

    Stryker, Joint Replacement

    Niamh Grano

    Sr. Communications Manager

    [email protected]

    201.831.5589

    Stryker Logo (PRNewsfoto/Stryker)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stryker-showcases-next-generation-of-mako-smartrobotics-at-aaos-2025-annual-meeting-302397425.html

    SOURCE Stryker

    Get the next $SYK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    9/10/2024$405.00Outperform
    Wolfe Research
    5/30/2024$372.00Neutral
    Goldman
    5/22/2024$392.00Hold → Buy
    Needham
    1/31/2024$315.00 → $360.00Hold → Buy
    Canaccord Genuity
    10/20/2023$345.00Buy
    ROTH MKM
    9/5/2023$310.00 → $315.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup resumed coverage on Stryker with a new price target

      Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00

      2/26/25 7:17:53 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously

      12/2/24 7:02:55 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Wolfe Research initiated coverage on Stryker with a new price target

      Wolfe Research initiated coverage of Stryker with a rating of Outperform and set a new price target of $405.00

      9/10/24 8:01:33 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

      Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain. PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and is an intersection of its two core competencies: radiofre

      5/19/25 1:01:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker declares an $0.84 per share quarterly dividend

      Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150

      5/8/25 8:00:00 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker reports first quarter 2025 operating results

      Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84  First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        13.4        %         (0.8)        %         14.2        %         3.5        %         10.7        %Orthopaedics    

      5/1/25 4:05:00 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    SEC Filings

    See more
    • SEC Form S-8 filed by Stryker Corporation

      S-8 - STRYKER CORP (0000310764) (Filer)

      5/30/25 4:16:27 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Stryker Corporation

      SD - STRYKER CORP (0000310764) (Filer)

      5/23/25 10:35:54 AM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Stryker Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STRYKER CORP (0000310764) (Filer)

      5/13/25 5:29:41 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider King Debra

      3 - STRYKER CORP (0000310764) (Issuer)

      6/4/25 4:42:25 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr covered exercise/tax liability with 1,005 shares, decreasing direct ownership by 28% to 2,643 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:43:32 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care
    • Amendment: VP, Chief Accounting Officer Berry William E Jr sold $211,370 worth of shares (755 units at $279.96), decreasing direct ownership by 29% to 1,853 units (SEC Form 4)

      4/A - STRYKER CORP (0000310764) (Issuer)

      5/23/25 7:39:38 PM ET
      $SYK
      Medical/Dental Instruments
      Health Care